Trials / Active Not Recruiting
Active Not RecruitingNCT05009329
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 315 (actual)
- Sponsor
- Allist Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JAB-21822 | JAB-21822 will be administered orally |
| DRUG | JAB-21822 | JAB-21822 will be administered orally |
| DRUG | JAB-21822 | JAB-21822 will be administered orally |
Timeline
- Start date
- 2021-07-26
- Primary completion
- 2026-05-01
- Completion
- 2026-12-01
- First posted
- 2021-08-17
- Last updated
- 2026-03-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05009329. Inclusion in this directory is not an endorsement.